THBS1+myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1

Julie Giraud, Domitille Chalopin,Eloise Ramel, Thomas Boyer,Atika Zouine, Marie-Alix Derieppe,Nicolas Larmonier, Olivier Adotevi,Brigitte Le Bail, Jean-Frederic Blanc,Christophe Laurent, Laurence Chiche,Marc Derive, Macha Nikolski,Maya Saleh

CELL REPORTS(2024)

引用 0|浏览6
暂无评分
摘要
Hepatocellular carcinoma (HCC) is an inflammation -associated cancer arising from viral or non -viral etiologies including steatotic liver diseases (SLDs). Expansion of immunosuppressive myeloid cells is a hallmark of inflammation and cancer, but their heterogeneity in HCC is not fully resolved and might underlie immunotherapy resistance. Here, we present a high -resolution atlas of innate immune cells from patients with HCC that unravels an SLD-associated contexture characterized by influx of inflammatory and immunosuppressive myeloid cells, including a discrete population of THBS1+ regulatory myeloid (Mreg) cells expressing monocyte- and neutrophil-affiliated genes. THBS1+ Mreg cells expand in SLD-associated HCC, populate fibrotic lesions, and are associated with poor prognosis. THBS1+ Mreg cells are CD163+ but distinguished from macrophages by high expression of triggering receptor expressed on myeloid cells 1 (TREM1), which contributes to their immunosuppressive activity and promotes HCC tumor growth in vivo. Our data support myeloid subset -targeted immunotherapies to treat HCC.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要